289 related articles for article (PubMed ID: 31239823)
1. Prostate Biopsy Features: A Comparison Between the Pre- and Post-2012 United States Preventive Services Task Force Prostate Cancer Screening Guidelines With Emphasis on African American and Septuagenarian Men.
Shah N; Ioffe V; Cherone S
Rev Urol; 2019; 21(1):1-7. PubMed ID: 31239823
[TBL] [Abstract][Full Text] [Related]
2. A Trend Toward Aggressive Prostate Cancer.
Shah N; Ioffe V
Rev Urol; 2020; 22(3):102-109. PubMed ID: 33239969
[TBL] [Abstract][Full Text] [Related]
3. Prostate Biopsy Characteristics: A Comparison Between the Pre- and Post-2012 United States Preventive Services Task Force (USPSTF) Prostate Cancer Screening Guidelines.
Shah N; Ioffe V; Huebner T; Hristova I
Rev Urol; 2018; 20(2):77-83. PubMed ID: 30288144
[TBL] [Abstract][Full Text] [Related]
4. Increasing aggressive prostate cancer.
Shah N; Ioffe V; Chang JC
Can J Urol; 2022 Dec; 29(6):11384-11390. PubMed ID: 36495581
[TBL] [Abstract][Full Text] [Related]
5. Prostate biopsy characteristics: A comparison between pre- and post- United States Preventive Service Task Force Prostate Cancer Screening Guidelines of 2012.
Shah N; Huebner T; Ioffe V; Hum R
Rev Urol; 2017; 19(1):25-31. PubMed ID: 28522927
[TBL] [Abstract][Full Text] [Related]
6. Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.
Perez TY; Danzig MR; Ghandour RA; Badani KK; Benson MC; McKiernan JM
Urology; 2015 Jan; 85(1):85-9. PubMed ID: 25440819
[TBL] [Abstract][Full Text] [Related]
7. Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening.
Zakaria AS; Dragomir A; Brimo F; Kassouf W; Tanguay S; Aprikian A
BMC Urol; 2018 Aug; 18(1):69. PubMed ID: 30126402
[TBL] [Abstract][Full Text] [Related]
8. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
[TBL] [Abstract][Full Text] [Related]
9. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
Kelly SP; Anderson WF; Rosenberg PS; Cook MB
Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
[TBL] [Abstract][Full Text] [Related]
10. US Preventive Services Task Force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses.
Gejerman G; Ciccone P; Goldstein M; Lanteri V; Schlecker B; Sanzone J; Esposito M; Rome S; Ciccone M; Margolis E; Simon R; Guo Y; Pentakota SR; Sadeghi-Nejad H
Investig Clin Urol; 2017 Nov; 58(6):423-428. PubMed ID: 29124241
[TBL] [Abstract][Full Text] [Related]
11. Abrogation of survival disparity between Black and White individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation.
Kim IE; Jang TL; Kim S; Modi PK; Singer EA; Elsamra SE; Kim IY
Cancer; 2020 Dec; 126(23):5114-5123. PubMed ID: 32888321
[TBL] [Abstract][Full Text] [Related]
12. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ
Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781
[TBL] [Abstract][Full Text] [Related]
13. Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer-Specific Mortality.
Burgess L; Aldrighetti CM; Ghosh A; Niemierko A; Chino F; Huynh MJ; Efstathiou JA; Kamran SC
JAMA Netw Open; 2022 May; 5(5):e2211869. PubMed ID: 35576008
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
15. The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients.
Dell'Atti L
J BUON; 2015; 20(6):1601-5. PubMed ID: 26854458
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.
Schröder FH; Roobol-Bouts M; Vis AN; van der Kwast T; Kranse R
Urology; 2001 Jan; 57(1):83-90. PubMed ID: 11164149
[TBL] [Abstract][Full Text] [Related]
17. Rates of clinically significant prostate cancer in African Americans increased significantly following the 2012 US Preventative Services Task Force recommendation against prostate specific antigen screening: A Single Institution Retrospective Study.
Arace J; Flores V; Monaghan T; Robins D; Karanikolas N; Winer A; Weiss J
Int J Clin Pract; 2020 Feb; 74(2):e13447. PubMed ID: 31750596
[TBL] [Abstract][Full Text] [Related]
18. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.
Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ
Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328
[TBL] [Abstract][Full Text] [Related]
19. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
